Finoriq research workspace
Alto Neuroscience, Inc. (ANRO) SEC Filings & Filing Highlights
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Review ANRO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
- Company
- Alto Neuroscience, Inc. (ANRO)
- Ticker
- ANRO
- Market Cap
- $1B
- Latest Price
- $26.11
- Industry
- Biotech & Pharma
Alto Neuroscience, Inc. (ANRO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Alto Neuroscience, Inc. (ANRO).
| Event | Form | Date |
|---|---|---|
| Appointment of Andrew Miller, Ph.D. to the Board On May 27, 2026, the Board of Directors (the “...Appointment of Andrew Miller, Ph.D. to the Board On May 27, 2026, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Com... | 8-K5.02 | 2026-05-28 |
| Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business HighlightsAlto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights | 8-K2.02 | 2026-05-13 |
| On May 12, 2026, the Company held the Annual Meeting. The stockholders considered four proposal...On May 12, 2026, the Company held the Annual Meeting. The stockholders considered four proposals, each of which is described in more detail... | 8-K5.07 | 2026-05-13 |
| (e) Equity Plan Amendments As noted in Item 5.07 below, at the Alto Neuroscience, Inc. (the “Co...(e) Equity Plan Amendments As noted in Item 5.07 below, at the Alto Neuroscience, Inc. (the “Company”) 2026 annual meeting of stockholders... | 8-K5.02 | 2026-05-13 |
| Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and High...Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements | 8-K8.01 | 2026-04-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.